Al's Comment:

This is a new form of targeted radiation.   We did a webinar about it:   They reported on the early results of their phase 1 trial, which was a dose escalation trial. They reported an amazing median survival of 10 months.  They did not have an external control group but in general, people with leptomeningeal mets only live 2 weeks to 4 months.   As the find the correct dosages it should get better. And as I always say - combinations are the way to cure these things. In the past, the main problem was that nothing really had time to work.  Now, if you could buy 10 months - that gives you a lot of time for other treatments to work. Very exciting. 
Disclaimer: Plus Therapeutics is a sponsor of our organization. 

Posted on: 08/12/2023

Plus Therapeutics Reports ReSPECT-LM Phase 1 Trial Data at the 2023 SNO/ASCO CNS Cancer Conference


Click HERE to return to brain tumor news headlines.

Our privacy / cookie policy has changed.
Click HERE to read it!